StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a research note released on Wednesday. The firm issued a hold rating on the biotechnology company’s stock.
Pulmatrix Trading Down 1.9 %
Shares of PULM stock opened at $2.04 on Wednesday. The firm has a market capitalization of $7.45 million, a PE ratio of -0.53 and a beta of 0.92. The firm has a fifty day simple moving average of $1.87 and a two-hundred day simple moving average of $1.88. Pulmatrix has a 12 month low of $1.55 and a 12 month high of $3.14.
Pulmatrix (NASDAQ:PULM – Get Free Report) last announced its quarterly earnings results on Thursday, March 28th. The biotechnology company reported ($0.57) EPS for the quarter. The business had revenue of $2.20 million for the quarter. Pulmatrix had a negative net margin of 193.49% and a negative return on equity of 63.94%.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Further Reading
- Five stocks we like better than Pulmatrix
- Short Selling: How to Short a Stock
- MarketBeat Week in Review – 4/22 – 4/26
- What is the Australian Securities Exchange (ASX)
- 3 Stocks Leading the U.S. Agriculture Comeback
- 3 Grocery Stocks That Are Proving They Are Still Essential
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
